Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part B Reforms: MedPAC Moving Forward With 'Drug Value Program' Proposal

Executive Summary

Even under most ambitious timeline, new competitive-bidding approach would not start before 2022 – and that assumes Congress has appetite for the legislation with an already full plate of health care work to do. But new ideas in Part B are worth watching.

You may also be interested in...



Senate Finance Panel’s New Legislative Staffer Kaltenboeck Likes QALYs For Valuing Drugs

Anna Kaltenboeck joins the committee from Memorial Sloan Kettering’s health policy group, which has been an active participant in US drug pricing reform policy development and a critic of the biopharma industry, often through public commentary by its director, Peter Bach.

Price Arbitration In Medicare: MedPAC Supportive But Congress Running Out Of Time

In its June report to Congress, the Medicare Payment Advisory Commission expands upon previous recommendations for establishing a binding arbitration process to control drug prices in Medicare.

Part D Brand Discounts May Be More Useful In Catastrophic Phase, House Panel Told

Medicare Payment Advisory Commission executive director Mathews suggests at April 30 hearing that manufacturers should bear more “liability” for catastrophic coverage in Medicare Part D.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS120166

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel